Celcuity Seeks FDA Nod for REVTORPYK in PIK3CA-Mutant Breast Cancer…

Event summary

Celcuity submitted an sNDA to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
The submission follows positive Phase 3 VIKTORIA-1 trial results showing a 50% reduction in disease progression risk versus alpelisib plus fulvestrant.
REVTORPYK-triplet (gedatolisib + fulvestrant + palbociclib) achieved 11.1 months median PFS vs. 5.6 months with alpelisib plus fulvestrant.
REVTORPYK-doublet (gedatolisib + fulvestrant) showed 11.3 months median PFS vs. 5.6 months with alpelisib plus fulvestrant.
The FDA previously approved REVTORPYK for PIK3CA wild-type HR+/HER2- advanced breast cancer in July 2026.

The big picture

Celcuity's sNDA submission represents a strategic push to broaden REVTORPYK's addressable market, targeting a subset of HR+/HER2- breast cancer patients with PIK3CA mutations. The move comes amid growing competition in targeted oncology therapies, where combination regimens are increasingly becoming the standard of care. Success here could position Celcuity as a key player in precision medicine for breast cancer, though regulatory and commercial hurdles remain.

What we're watching

Regulatory Timeline: The pace at which the FDA reviews Celcuity's sNDA will determine REVTORPYK's market availability for PIK3CA-mutant patients.
Competitive Positioning: Whether REVTORPYK can differentiate itself against existing PI3K/mTOR inhibitors in the HR+/HER2- breast cancer space.
Commercial Strategy: How Celcuity plans to expand REVTORPYK's reach beyond the PIK3CA wild-type indication into the larger PIK3CA-mutant population.